BRAF and melanoma: Multiple in vitro studies have shown that MITF-high melanoma cells are more sensitive to small-molecule BRAF inhibition than MITF-low cells8–11, but the connection between melanoma cell phenotype and BRAF inhibitor sensitivity is affected by the duration of drug exposure12,13, co-occurring resistance aberrations, and in vivo environmental factors14–16.